Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Diffuse Large B-Cell Lymphoma

Known as: large cell diffuse lymphoma, DLBCL, Lymphoma, Diffuse Large Cell 
A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type… Expand
National Institutes of Health

Related topics

Related topics

38 relations

Narrower (4)

Anaplastic LymphomaAngioendotheliomatosisMalignant lymphoma centroblastic, diffuseT-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Atypical lymphocyteB lymphoblastB-Cell Lymphoma 6 ProteinB-Lymphocytes
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Advances in cancer immunotherapy 2019 – latest trends
Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety… Expand
  • figure 1
  • figure 2
Review
2019
Review
2019
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed the treatment landscape of B-cell non… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Review
2019
Review
2019
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
Chimeric antigen receptor (CAR) T‐cell therapy represents a major advancement in personalized cancer treatment. In this strategy… Expand
Review
2019
Review
2019
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. Two CAR T-cell… Expand
Review
2019
Review
2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Summary Background Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified using gene-expression… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Review
2019
Review
2019
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
Review
2019
Review
2019
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Abstract Background Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that… Expand
Review
2019
Review
2019
RAPID: Early Classification of Explosive Transients using Deep Learning
We present RAPID (Real-time Automated Photometric IDentification), a novel time-series classification tool capable of… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Review
2018
Review
2018
Hijacking of the AP-1 Signaling Pathway during Development of ATL
Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of a fatal malignancy known as adult T-cell leukemia (ATL… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Review
2018
Review
2018
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
Purpose of ReviewGenetically engineered T cells expressing a chimeric antigen receptor (CAR-T) targeting specific antigens… Expand
  • table 1
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE